NVOX
Defiance Daily Target 2x Long NVO ETF
stock NYSE ETF

I wrote this a while back on another sub not sure if x post is allowed but here it is:
Max tendies with NVO
\*\*Not financial advise. I am a degen gambler that was dropped on the head many times as a child.
Gonna do this without the bells and whistles, just the info you need. Here's why NVO is about to print money. This is not some pump and dump company. This is Novo one of the largest pharma companies on the planet that's been beaten down of late. Get on it.
First, let's talk about the real cash cow: **"Wegovy in a pill."** Novo just dropped some fire data from their Oasis 4 trial showing an average weight loss of **16.6%**. Let me repeat that: **16.6%!** That’s on par with the injectable version, but now it's a freaking pill. All the needle-haters out there are about to throw their money at this thing. Plus, Novo is already mass-producing this bad boy in the U.S. and has an FDA decision coming in Q4. While everyone's been worried about Lilly's oral drug, Novo is about to get first-to-market advantage and a head start on printing money. Lilly won't hit FDA until next year and Orfo is not as good!!
Second, they just body-slammed their biggest rival, Eli Lilly. Ozempic, their diabetes cash cow, just proved in a head-to-head trial that it reduces the risk of heart attacks and strokes by a whopping **23%**. It solidifies their dominance in the diabetes market and gives them a huge advantage in the fight for market share.
So, while the stock has been a little shaky lately, it's just been a consolidation period before the launch. With a potential blockbuster oral drug and a market-leading diabetes med that just proved its superiority, the fundamentals are solid. This isn't a risky bet, this is a **💎🙌** play.
**My positions -- 100 shares, 9/26 NVO $60 put (hope to get assigned), NVO75 calls Jun 18, 2026 (5X) and 1000 NVOX shares (2X NVO ETF).**
Here is a story from Fierce Biotech: [https://www.fiercepharma.com/pharma/novo-nordisk-pads-case-wegovy-pill-oral-obesity-asset-nears-fda-decision](https://www.fiercepharma.com/pharma/novo-nordisk-pads-case-wegovy-pill-oral-obesity-asset-nears-fda-decision)

I wrote this a while back on another sub not sure if x post is allowed but here it is:
Max tendies with NVO
\*\*Not financial advise. I am a degen gambler that was dropped on the head many times as a child.
Gonna do this without the bells and whistles, just the info you need. Here's why NVO is about to print money. This is not some pump and dump company. This is Novo one of the largest pharma companies on the planet that's been beaten down of late. Get on it.
First, let's talk about the real cash cow: **"Wegovy in a pill."** Novo just dropped some fire data from their Oasis 4 trial showing an average weight loss of **16.6%**. Let me repeat that: **16.6%!** That’s on par with the injectable version, but now it's a freaking pill. All the needle-haters out there are about to throw their money at this thing. Plus, Novo is already mass-producing this bad boy in the U.S. and has an FDA decision coming in Q4. While everyone's been worried about Lilly's oral drug, Novo is about to get first-to-market advantage and a head start on printing money. Lilly won't hit FDA until next year and Orfo is not as good!!
Second, they just body-slammed their biggest rival, Eli Lilly. Ozempic, their diabetes cash cow, just proved in a head-to-head trial that it reduces the risk of heart attacks and strokes by a whopping **23%**. It solidifies their dominance in the diabetes market and gives them a huge advantage in the fight for market share.
So, while the stock has been a little shaky lately, it's just been a consolidation period before the launch. With a potential blockbuster oral drug and a market-leading diabetes med that just proved its superiority, the fundamentals are solid. This isn't a risky bet, this is a **💎🙌** play.
**My positions -- 100 shares, 9/26 NVO $60 put (hope to get assigned), NVO75 calls Jun 18, 2026 (5X) and 1000 NVOX shares (2X NVO ETF).**
Here is a story from Fierce Biotech: [https://www.fiercepharma.com/pharma/novo-nordisk-pads-case-wegovy-pill-oral-obesity-asset-nears-fda-decision](https://www.fiercepharma.com/pharma/novo-nordisk-pads-case-wegovy-pill-oral-obesity-asset-nears-fda-decision)